Is an artificial pancreas covered by insurance?

Many FDA-approved AID systems are covered by private insurance and Medicare, but coverage varies by plan. It is important to check with your insurance provider and work with your diabetes care team to navigate prior authorization requirements.

Can people with Type 2 diabetes use a closed loop system?

Some systems, like the Omnipod 5, have received FDA approval for use in adults with Type 2 diabetes who use insulin. Coverage and eligibility criteria may differ from Type 1 diabetes patients, so speak with your endocrinologist for personalized guidance.

FDA-Approved Artificial Pancreas Systems 2025

Key takeaways

✓Covers all major FDA-approved AID systems available in 2025
✓Explains how closed loop technology works in simple terms
✓Includes eligibility guidance to help readers take next steps

What Is an Artificial Pancreas?

An artificial pancreas, also known as a closed loop system or automated insulin delivery (AID) system, is a technology that automatically monitors blood glucose levels and delivers insulin without constant manual input. By combining a continuous glucose monitor (CGM), an insulin pump, and a control algorithm, these systems mimic the function of a healthy pancreas more closely than any previous diabetes technology.

As of 2025, several closed loop systems have received FDA approval, offering people with Type 1 diabetes — and increasingly Type 2 — unprecedented glucose control and quality of life improvements.

How Closed Loop Systems Work

Closed loop systems operate through three integrated components:

Continuous Glucose Monitor (CGM): Measures glucose levels in real time, typically every 5 minutes.
Insulin Pump: Delivers rapid-acting insulin subcutaneously throughout the day and night.
Control Algorithm: Processes CGM data and automatically adjusts insulin delivery to keep glucose within a target range.

The result is a system that reacts to rising or falling glucose levels automatically, reducing the burden of constant diabetes self-management.

FDA-Approved Closed Loop Systems in 2025

1. Medtronic MiniMed 780G

The MiniMed 780G is one of the most advanced AID systems on the market. It uses the Guardian 4 CGM and features SmartGuard technology, which automatically adjusts basal insulin, delivers correction boluses, and suspends insulin delivery when needed. The system targets a glucose level of 100 mg/dL, 110 mg/dL, or 120 mg/dL, offering flexibility for individual needs. Clinical studies have shown users spend significantly more time in range compared to earlier systems.

2. Tandem Diabetes Care Control-IQ Technology

The Tandem t:slim X2 pump with Control-IQ technology remains a leading FDA-approved AID system in 2025. It pairs with the Dexcom G7 CGM and uses predictive algorithms to increase, decrease, or suspend insulin delivery. Control-IQ also delivers automatic correction boluses when glucose is predicted to exceed 180 mg/dL. A Sleep Activity feature further tightens control overnight. Tandem has continued to release software updates that users can download at home, keeping the system current without hardware replacement.

3. Insulet Omnipod 5

The Omnipod 5 Automated Insulin Delivery System is the first tubeless, wearable AID system to receive FDA approval. It uses a waterproof pod worn directly on the skin and integrates with the Dexcom G6 or G7 CGM. Its SmartAdjust algorithm adapts insulin delivery every 5 minutes. A major advantage is its smartphone control capability, allowing users to manage the system directly from a compatible Android or iOS device. Omnipod 5 is FDA approved for people as young as 2 years old.

4. Beta Bionics iLet Bionic Pancreas

Approved by the FDA in 2023 and continuing to expand availability in 2025, the iLet Bionic Pancreas represents a significant leap forward. Unlike other systems, iLet requires only the user's body weight to initialize — no carb ratios or basal rates needed. It uses a proprietary algorithm that learns and adapts over time. The iLet pairs with the Dexcom G6 and is designed to be as user-friendly as possible, lowering the management burden considerably.

What About Dual-Hormone Systems?

Research into dual-hormone systems that deliver both insulin and glucagon (or pramlintide) is ongoing, but as of 2025, no dual-hormone closed loop system has received full FDA approval for commercial use. These systems hold promise for preventing hypoglycemia more effectively and remain an exciting frontier in diabetes technology research.

Who Qualifies for a Closed Loop System?

Most FDA-approved AID systems are indicated for people with Type 1 diabetes, though some, like Omnipod 5, have expanded labeling for Type 2 diabetes. Eligibility typically depends on your age, insulin regimen, and insurance coverage. Consulting your endocrinologist is the best first step to determine which system aligns with your lifestyle and clinical needs.

The Bottom Line

The landscape of FDA-approved closed loop systems in 2025 is more robust than ever. Whether you prioritize tubeless design, smartphone integration, or algorithm simplicity, there is likely a system suited to your needs. These technologies are not cures, but they represent the most powerful tools available today for achieving better glucose control and reducing the daily burden of diabetes management.

Frequently asked questions

There is no single best system for everyone. The Omnipod 5, Tandem Control-IQ, Medtronic MiniMed 780G, and iLet Bionic Pancreas are all FDA approved and each offers unique advantages. Your lifestyle, CGM preference, and insurance coverage will help determine the right fit.

Editorial note

This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diabetes management. Last reviewed: July 16, 2026 by the MDS Diabetes editorial team.

What to do next

📚

Artificial Pancreas 2025: Which Closed Loop Systems Are FDA Approved